pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Itvisma
drug
save

onasemnogene abeparvovec

Marketedupdated 6mo ago
by Novartis Gene Therapies
Approved
community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying onasemnogene abeparvovec

  • phase4ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants Treated With Intrathecal Onasemnogene Abeparvovec-brve (OAV101B) (ITVISMA®): A U.S. Pragmatic Multicenter Study (STREAM)recruitingn=36
  • phase3Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trialsactive not recruitingn=20
  • phase3Single-Dose Gene Replacement Therapy Using for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copiescompletedn=2
  • phase3Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2completedn=30
  • phase3Single-Dose Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1completedn=33
  • phase3Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1completedn=22
  • phase1Study of Intrathecal Administration of Onasemnogene Abeparvovec-xioi for Spinal Muscular Atrophyterminatedn=32
  • phase3Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioiactive not recruitingn=85

News(3)

  • Details from Novartis’ failed cardiovascular trial offer ‘little silver lining’ for rivals
    Full data from the Phase 3 HORIZON trial of Novartis' pelacarsen failed to show any apparent benefit, leading analysts to further reduce the odds of success for Lp(a)-lowering competitors such as A…
    biospace · 9d ago
  • Forge’s Piteri-Molina on AI, Ohio and what’s next for gene therapy manufacturing
    The BioSpace 40 Under 40 honoree helped steer Forge’s sale to Ajinomoto. Now, Samantha Piteri-Molina sees opportunities in AI-driven analytics and Ohio’s gene therapy ecosystem—with a responsibilit…
    biospace · 12d ago
  • MedWatch Alert: FDA Investigating Serious Risk of Malignancy Linked to Zolgensma Gene Therapy
    FDA Investigating Serious Risk of Malignancy Linked to Zolgensma Gene Therapy: FDA Safety Communication
    fda_medwatch · 13d ago
brand
Itvisma
generic
onasemnogene abeparvovec-xioi
indication
Spinal Muscular Atrophy (SMA)
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 3h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?